CYT387 sulfate salt

• CAT Number: I000294
• CAS Number: 1056636-06-6
• Molecular Formula: C23H26N6O10S2
• Molecular Weight: 610.62
• Purity: ≥95%
• Synonyms: N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide; sulfuric acid
• Target: Stem Cell/Wnt
• Solubility: DMSO: ≥ 6.1 mg/mL
• Storage: Store at -20°C
• IC50: 11 nM/18 nM(JAK1/JAK2) [1]
• IUPAC Name: N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide;sulfuric acid
• InChI: InChI=1S/C23H22N6O2.2H2O4S/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29;2*1-5(2,3)4/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28);2*(H2,1,2,3,4)
• InChIKey: XJGPMRGWDSQVTN-UHFFFAOYSA-N
• SMILES: C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N.OS(=O)(=O)O.OS(=O)(=O)O

CYT387 sulfate salt（Cat No.:I000294）is a potent and selective inhibitor of Janus kinase 1 and 2 (JAK1/JAK2), enzymes involved in cytokine signaling and hematopoiesis. This compound is primarily investigated for its therapeutic potential in myeloproliferative neoplasms and other hematological disorders characterized by JAK pathway dysregulation. By inhibiting JAK1 and JAK2, CYT387 sulfate salt disrupts abnormal signaling, leading to reduced proliferation of malignant cells. Its effectiveness in clinical studies highlights its promise as a targeted therapy, offering new avenues for treatment in conditions driven by JAK-mediated pathways.

Reference

[1]. Pardanani A, et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia, 2009, 23(8), 1441-1445.
[2]. Monaghan KA, et al. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia, 2011, 25(12), 1891-1899.
[3]. Tyner JW, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 2010, 115(25), 5232-5240.